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Abstract
Increased vascular permeability is an early event characteristic of tissue ischemia and angiogenesis. Although VEGF family
members are potent promoters of endothelial permeability the role of placental growth factor (PlGF) is hotly debated. Here
we investigated PlGF isoforms 1 and 2 and present in vitro and in vivo evidence that PlGF-1, but not PlGF-2, can inhibit
VEGF-induced permeability but only during a critical window post-VEGF exposure. PlGF-1 promotes VE-cadherin expression
via the trans-activating Sp1 and Sp3 interaction with the VE-cadherin promoter and subsequently stabilizes transendothelial
junctions, but only after activation of endothelial cells by VEGF. PlGF-1 regulates vascular permeability associated with the
rapid localization of VE-cadherin to the plasma membrane and dephosphorylation of tyrosine residues that precedes
changes observed in claudin 5 tyrosine phosphorylation and membrane localization. The critical window during which PlGF-
1 exerts its effect on VEGF-induced permeability highlights the importance of the translational significance of this work in
that PLGF-1 likely serves as an endogenous anti-permeability factor whose effectiveness is limited to a precise time point
following vascular injury. Clinical approaches that would pattern nature’s approach would thus limit treatments to precise
intervals following injury and bring attention to use of agents only during therapeutic windows.
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Introduction
Increased vascular permeability is an inciting event in numerous
human vascular pathologies such as ischemic stroke, diabetic
complications, tumorogenesis and rheumatoid arthritis [1,2,3].
Intercellular junctions between endothelial cells control vascular
permeability and integrity. This barrier function requires the
expression and organization of VE-cadherin and claudin-5, which
are essential components of adherens junctions (AJs) and tight
junctions (TJs) respectively [1,4] in the blood-brain and blood-
retinal barriers. TJs and AJs may act as two resistors that act in
series with the TJs more restrictive to ions and small molecules
than the AJs [3,5,6]. As opposed to epithelial cells where the AJs
and TJs can clearly be distinguished by ultrastructural analysis, in
endothelial cells of the blood-brain and blood retinal barrier these
junctional complexes are intermingled [1,7]. Cells require AJ
formation to build TJs [6,8] and recent reports indicate that co-
ordinated disruption of VE-cadherin intracellular interactions
culminates in the restructuring of both AJs and TJs and the
subsequent opening of endothelial cell-cell junctions [1,4,7].
Furthermore, VE-cadherin is involved in the formation of TJs,
regulates claudin-5 expression and is required for VEGF-induced
endothelial cell survival [1,7,9].
VEGF increases vascular permeability by inducing VE cadherin
destabilization [7] and inducing the endocytosis of both the AJ
protein VE-cadherin [10] and the TJ protein occluding [3,11]
through a phosphorylation-dependent signalling pathway. The
VEGF family includes VEGF-A and placenta growth factor (PlGF)
which can exist as homo- or heterodimers [12,13]. PlGF, which
has a 42% amino acid sequence identity with VEGFA [14], occurs
in at least four isoforms, PlGF-1, PlGF-2, PlGF-3, PlGF-4 as a
result of alternative splicing [14,15]. PlGF-2 has high heparin
binding affinity whereas neither PlGF-1, PlGF-3 nor PlGF-4 bind
heparin. VEGF is considered to increase vascular permeability
through VEGFR-2, however, the role of PlGF, which specifically
binds VEGFR-1, has been more controversialwith both pro- and
anti-angiogenic effects proposed [15]. This is likely to in part be
due to the isoform of PlGF examined and the models used. Most
studies have focussed on PlGF-2 since this is the only isoform
present in the mouse [16,17]. PlGF-2 deficiency protects mice
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18076against vascular permeability [18] while mice overexpressing
PlGF-2 have enhanced VEGF-induced permeability [19,20]. The
latter is perhaps counterintuitive since VEGFR-1 is considered to
be a potent negative regulator of VEGFR-2 activity [21,22,23].
Exogenous PlGF-2 has been reported to have either no direct or a
direct effect on in vitro or in vivo permeability but, in general, most
studies agree that PlGF-2 enhances VEGF-induced permeability
[15,24,25,26,27,28,29]. The role of PlGF in angiogenesis is
unclear given a) the variance in outcomes of PlGF-2 blockade
on tumor angiogenesis [30,31] and b) PlGF-1 antagonizes VEGF-
induced angiogenesis in some models [27,32,33] but promotes
angiogenesis in others [34].
Here, we present evidence demonstrating that PlGF-1, but not
PlGF-2, can inhibit VEGF-induced endothelial cell permeability in
the normal vasculature but only during a critical window
approximately 6 hours after VEGF induction of permeability. We
show PlGF-1 stabilizes both AJs and TJs in vitro using endothelial
monolayers and in vivo using the retinal vasculature of mice. PlGF-1
stabilization of junctions occurs by a carefully orchestrated series of
events including dephosphorylation of VE-cadherin, reduced
cleavage of VE-cadherin, and increased VE-cadherin expression
through transactivation of Sp1 and Sp3 within the VE-cadherin
promoter. These studies strongly suggest that early detection is
paramount to therapeutic success and that if therapeutic agents are
to be administered in the identical manner as nature has carefully
orchestratedthenasmuchattentionmustbegiventowhenatherapy
is initiated and its dosing regimen as is typically given to identifying
the actual therapeutic agent. Our results also provide validity to the
intermittent intravitreal administration of anti-VEGF agents as an
optimal therapeutic strategies rather than sustained release.
Results
PlGF-1, but not PlGF-2, exerts a temporal regulation of
VEGF-induced permeability
Given the controversy regarding the effect of PlGF on vascular
permeability we first asked whether there was a temporal
dependence of the effect of PlGF on VEGF-induced vascular
permeability and if this was isoform dependent. We have identified
a critical window during which hPlGF-1 can inhibit VEGF-induced
permeability (Fig. 1a). The addition of VEGF to cultured retinal
microvascular endothelial cells caused a significant decrease in
transendothelial resistance and an increase in the transendothelial
flux of flourescent dextran, which was sustained over a 24 hour
period (Fig. 1a, b). Furthermore this was dose-dependent with
200 ng/ml hPlGF-1 exerting the maximum inhibition of VEGF-
induced permeability while 10 ng/ml hPlGF-1 only had a weak
effect. Neither the simultaneous treatment of cultured retinal
endothelial cells with hPlGF-1 and VEGF (Fig. 1a,b) nor 3 or
24 hourpre-treatmentwithhPlGF-1followed byVEGF (Fig.2)had
any significant effect on VEGF-induced permeability. However,
addition of hPlGF-1 6 hr post-treatment with VEGF resulted in a
complete inhibition of VEGF-induced permeability (P,0.05)
(Fig. 1a, b). By contrast, 24 hr post-treatment with hPlGF-1 had
no significant effect on VEGF-induced permeability (Fig. 2).
Neutralizing antibody to remove secreted VEGF caused a modest
decrease in permeability and abolished any hPlGF-1-induced effect
suggesting that even the constitutive secretion of endogenous VEGF
is sufficient to affect barrier function (Fig. 2). By contrast, hPlGF-2
had no effect on in vitro barrier function either when applied alone
or in combination with VEGF (Fig. 1c,d).
To confirm that the temporal effect of hPlGF-1 we repeated our
studies in mice. Intravitreal injection of VEGF in C57Bl6 mice
resulted in significant intraretinal leakage of systemically intro-
duced fluorescent albumin. Similar to the culture data, neither
pretreatment, simultaneous treatment, 24 hour post-treatment
with hPlGF-1 nor treatment with mPlGF-2 resulted in any
significant change in VEGF-induced permeability (Fig. 1e).
However, intravitreal injection of hPlGF-1 6 hr post-treatment
with VEGF resulted in a complete inhibition of VEGF-induced
fluorescent albumin leakage into the retina. Confocal microscopy
of flat mount retinal preparations showed intraretinal fluorescent
albumin in greater than 90% of the retina in VEGF treated
animals, confirming increased vascular leakage compared to
vehicle only controls (Fig. 1f). By marked contrast, minimal
vascular leakage of fluorescent albumin was observed in animals
receiving intravitreal injection of hPlGF-1 6 hr post-treatment
with VEGF while animals receiving pretreatment or simultaneous
treatment with hPlGF-1 showed considerable vascular leakage
(Fig. 1f). The ability of hPlGF-1 to block VEGF-induced
permeability when injected 6 hr following VEGF was dose-
dependent with 60 and 120 ng per eye almost completely blocking
fluorescence leakage while 10 ng per eye had no significant effect.
VEGFR-1 is a negative regulator of VEGFR-2 but only after
both receptors are activated
To determine whether endothelial permeability is regulated by
specific VEGF receptors subtypes, VEGF-E, selective for VEGFR-
2, was tested. VEGF-E did not induce detectable changes in
endothelial permeability indicating that VEGFR2 is not the
dominant receptor in regulating VEGF-induced permeability
(Fig. 3a,b). This was supported by neutralization of VEGFR-2
which only reduced VEGF-A induced permeability by less than
30% at 1 and 12 hours post VEGF injection, suggesting the
requirement for a second receptor. Blocking VEGFR-1 with a
neutralizing antibody abolished the effects of VEGF on the
changes in TER and permeability of the endothelial cell
monolayer, confirming that VEGF must bind to both VEGFR-1
and R-2 to elicit a maximal increase in permeability in cultured
cells (Fig 3a, b). Neutralizing antibodies both to VEGFR-1 and
VEGFR-2 were able to block VEGF-induced vascular permeabil-
ity in mice (Fig. 3c).
PlGF-1 stabilizes both AJs and TJs
Because the barrier function of the endothelial monolayer is
closely associated with both TJs and AJs [1,35,36] we performed
immunohistochemistry to determine the temporal and spatial
changes in junctional complexes following VEGF and hPlGF-1
treatment both in vitro and in vivo. Endothelial monolayers
demonstrated strong staining of the lateral membranes for both
VE-cadherin, claudin-5 (Fig. 4) and ZO-1 (data not shown). When
exposed to hPlGF-1 alone cells retained intact interendothelial
cell-to-cell contact (Fig. 5) with an intense increase in inter-
endothelial junctional VE-cadherin staining at 12 and 24 hours
post treatment with no change in the TJ proteins (Fig. 4). In
contrast, VEGF-treated cells showed a rapid loss of both tight and
adherens junctional complex integrity over a 24 hour period. For
VE-cadherin, a reduction of staining at the intercellular junctions
with a more particulate staining profile was observed by 5-minute
post VEGF treatment and the formation of numerous intercellular
gaps was observed by 12 hours (Fig. 4). Changes in claudin-5 and
ZO-1 staining were not observed until 1 hour post VEGF
treatment consistent with reports that changes in TJs occur later
than alterations of AJs [7,36]. Addition of hPlGF-1 at 6 hours post
VEGF treatment significantly restored VE-cadherin, claudin 5
and ZO-1 staining within 1 hour. Staining intensity for VE-
cadherin increased further over 24 hours and loss of cell-cell
contacts was prevented (Fig. 4).
PlGF-1 Antagonizes VEGF-Induced Permeability
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proteins expression and changes in paracellular vascular perme-
ability of the mouse retinal vasculature (Fig. 6). A typical staining
pattern of the vascular network that demarcates the lateral
membranes of microvascular endothelial cells was observed for
both VE-cadherin and claudin-5 in mouse eyes without injection,
Figure 2. The effect of PlGF-1 on VEGFA-induced permeability is highly dependent on the timing and order of exposure. (a) Effect of
VEGFA alone, hPlGF-1 pretreatment for 3 hr or 24 hr exposure to VEGF and hPlGF-1 24 hours post VEGF on temporal changes in transendothelial
resistance across a microvascular endothelial monolayer grown on a transwell insert effected by (n=4 independent experiments). VEGFA and hPlGF-1
were used at 100 ng/ml. (b) paracellular macromolecular permeability to 40 kDa Dextran-FITC using the conditions described in (a) (n=4
independent experiments). (c) The effect of neutralization of endogenous VEGF on PlGF-induced transendothelial resistance (n=4 independent
experiments). VEGFA neutralizing antibody was used at 10 mg/ml. (d) Paracellular macromolecular permeability to 40 kDa Dextran-FITC using the
conditions described in (c) (n=4 independent experiments). Data are represented as means 6 s.e.m. *p,0.05, ** by p,0.01 (Student’s t test and
ANOVA for multiple comparisons).
doi:10.1371/journal.pone.0018076.g002
Figure 1. PlGF-1, but not PlGF-2, exerts a temporal-dependent regulation of VEGFA-induced permeability. (a)&( c) Temporal changes
in transendothelial resistance across a microvascular endothelial monolayer grown on a Transwell insert with the five conditions including the
unstimulated group, vehicle (saline), VEGFA alone, PlGF alone, simultaneous VEGFA + PlGF and PlGF 6 hours post VEGFA (n=5 independent
experiments). VEGFA was used at 100 ng/ml. Data for hPlGF-1 and hPlGF-2 is at 100 ng/ml with the exception of PlGF 6 hours post VEGFA in which
results are shown for PlGF at 10 ng/ml (a), 100 ng/ml (b) and 200 nglml (c). hPlGF-1 was used in (a) and hPlGF-2 in (c). (b)&( d) Show paracellular
macromolecular permeability to 40 kDa Dextran-FITC using the conditions described above for (a) and (c) (n=5 independent experiments). In the
case of PlGF 6 hours or 24 hours post VEGF, Transwell inserts were transferred to new wells containing basal medium without fluorescent dextran. (e)
Leakage of systemic FITC-labeled albumin into the retina of C57BL/6 mice receiving one of the following intravitreal injections: VEGF; hPlGF-1 or
mPlGF-2; VEGF plus hPlGF-1 or mPlGF-2; 0.9% saline vehicle; VEGF followed by hPlGF-1 or mPlGF-2 6 or 24 hours later; VEGF followed by 0.9% saline 6
or 24 hours later. VEGF was given at a concentration of 60 ng/ml while hPlGF-1 and mPlGF-2 were injected at 10, 60 or 120 ng/ml. 46 hours post the
first injection mice received tail vein injections of FITC-labeled albumin and retinas were taken for analysis 2 hours later (n=10-20 per group). (f)
Representative confocal microscopy showing dilated vessels and leakage of FITC-labeled albumin in the retinas of mice receiving vehicle only (i),
VEGF A (ii), simultaneous VEGF + hPlGF-1 (iii), VEGFA followed by hPlGF-1 6 hours later (iv), simultaneous VEGF + mPlGF-2 (v), or VEGFA followed by
mPlGF-2 6 hours later (vi). As shown in (g), PlGF-1 reduced Leakage of systemic FITC-labeled albumin into the retina of C57BL/6 mice receiving
intravitreal injection of VEGF A in a dose-dependent manner. Data are represented as means 6 s.e.m. *p,0.05, ** by p,0.01 (Student’s t test and
ANOVA for multiple comparisons). Scale bar =50 mM.
doi:10.1371/journal.pone.0018076.g001
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hPlGF-1 alone over a 48 hour period. Intravitreal injection of
VEGF resulted in an almost complete loss of staining of the
junctional network for greater than 90% of the retinal vessels
indicative of loss of junctional complexes and this was confirmed
by excessive leakage of fluorescent albumin into the retina (Fig. 6).
Figure 3. VEGFR-1 is a critical regulator of VEGF-induced permeability. (a) Temporal changes in transendothelial resistance across a
microvascular endothelial monolayer grown on a transwell insert treated with VEGFA alone (100 ng/ml), VEGFE alone (100 ng/ml), and VEGFA
(100 ng/ml) + a neutralizing antibody (2 mg/ml) to VEGFR-1 or VEGFR-2 (n=4 independent experiments). (b) Paracellular macromolecular
permeability to 40 kDa Dextran-FITC using the conditions described in (a) (n=4 independent experiments). (c) The effect of neutralizing antibodies
to VEGFR-1 (4 or 12 ng/eye) and VEGFR-2 (0.5 or 1.0 ng/eye) on VEGF-induced permeability in C57BL/6 mice. Neutralizing antibodies were given by
intravitreal injection and VEGF (60 ng/eye) was injected 6 hours later. 46 hours post the first injection mice received tail vein injections of FITC-
labeled albumin and retinas were taken for analysis 2 hours later (n=6 per group). Data are represented as means 6 s.e.m. *p,0.05, ** by p,0.01
(Student’s t test and ANOVA for multiple comparisons).
doi:10.1371/journal.pone.0018076.g003
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exhibited a pattern of VE-cadherin and claudin 5 staining similar
to that seen for controls in over 75% of the retina although a few
areas remained in which junctional complexes seemed to be less
well formed. However, if hPlGF-1 was given at the same time as
VEGF there was significant destabilization of the junctional
proteins although the effect was not as great as when VEGF was
given alone.
PlGF-1 reverses VEGF-induced phosphorylation of
VE-cadherin followed by claudin-5
VE-cadherin phosphorylation is believed to play a critical role
in vascular permeability as VEGF induces phosphorylation of VE-
cadherin in AJs and this parallels increases in cell permeability [1].
Putative phosphorylation sites on VE-cadherin include Y658,
Y685, Y731 and S665. Exogenous VEGF results in tyrosine
phosphorylation of VE-cadherin within 5 minutes, significantly
before phosphorylation of claudin-5 occurs. Similarly, dephos-
phorylation of VE-cadherin was evident within 5-10 minutes in
cells treated with hPlGF-1 at 6 hours post VEGF and this
occurred significantly earlier than dephosphorylation of claudin-5
(Fig. 7a–d). VE-Cadherin phosphorylation appeared to be
predominantly regulated at Y658 and Y731 (Fig. 7e). No change
in VE-cadherin phosphorylation was observed when hPlGF-1 was
given prior to, or in combination with, VEGF or when hPlGF-1
was administered alone. These observations show that VE-
cadherin phosphorylation occurs before claudin 5 phosphorylation
and is consistent with alterations in AJs preceding TJs. It has been
proposed that endothelial AJs can regulate TJs by VE-cadherin-
regulation of claudin-5 [7,36]. Consistent with previous reports
[37,38], phosphorylation of claudin-5 at T207 is associated with
increased permeability. Tyrosine phosphorylation of claudin-5
occurred within 15 minutes following VEGF treatment (Fig. 7).
Dephosphorylation of claudin-5 was evident only in cells treated
with hPlGF-1 at 6 hours post VEGF-induced permeability and not
when hPlGF-1 was given prior to, or in combination with, VEGF.
hPlGF-1 alone had no effect on claudin-5 phosphorylation status.
Neutralization of VEGFR-2 significantly decreases VEGF-in-
duced phosphorylation of both VE-cadherin and claudin-5 and
hPlGF-1 has no effect. By contrast, neutralization of VEGFR-1
significantly increased VEGF-induced phosphorylation of VE-
cadherin and claudin-5 and this was not influenced by hPlGF-1
Figure.
PlGF-1 promotes expression of VE-cadherin but not TJ
proteins
An increase in the levels of interendothelial junctional VE-
cadherin can result from recruitment of either pre-existing VE-
cadherin or newly synthesized molecules of VE-cadherin. To
distinquish between these two possibilities, the VE-cadherin
Figure 4. PlGF-1 stabilizes both AJs and TJs in vitro following VEGF-induced permeability. Representative pictures of confluent cultures
of microvascular endothelial cells treated with VEGFA alone or VEGFA followed by hPlGF-1 6 hours later triple stained for VE-cadherin (red), claudin-5
(green) and nuclei (DAPI) and assessed at different times over 24 hours using confocal microscopy. VEGFA and hPlGF-1 were used at 100 ng/ml. Scale
bar=100 mm.
doi:10.1371/journal.pone.0018076.g004
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analysis showed that VEGF only marginally affected VE-
cadherin expression (Fig. 8a). In contrast, after 1 hour of
hPlGF-1 treatment, the amount of VE-cadherin protein in-
creased to approximately 50% compared to untreated cells.
Extension of hPlGF-1 treatment time up to 24 hr sustained
significant VE-cadherin protein levels in endothelial cells.
Additionally, hPlGF-1 induced a marked time-dependent
increase in VE-cadherin protein expression in VEGF-stimulated
cells (Fig. 8a). To further explore the changes in VE-cadherin
protein levels in the context of membrane-association, a cell-
based ELISA assay was used to measure cell surface VE-
cadherin. hPlGF-1 -treated monolayers showed a strong increase
in the level of cell surface VE-cadherin by 1 hour (Fig. 8b). In
contrast, VEGF induced a significant reduction of the level of cell
surface VE-cadherin by 1 hour, while hPlGF-1 mediated a slight
submaximal increase by 12 hours in VEGF-stimulated cells
(Fig. 8b). RT-PCR revealed markedly increased expression of
VE-cadherin after hPlGF-1 treatment with the levels of VE-
cadherin mRNA increased 0.5 to 1 times and the most
pronounced increase was observed at 1 hr (Fig. 8c). VEGF
failed to induce any significant changes in VE-cadherin mRNA
and as expected, hPlGF-1 significantly elevated (,100%) the
amount of VE-cadherin mRNA in the VEGF-stimulated cells.
VEGF caused a reduction in occludin but this was not reversed
by exogenous hPlGF-1 even when applied 6 hours after VEGF
(Fig. 9). Neither VEGF nor hPlGF-1 caused detectable changes
in protein or mRNA expression of claudin 5.
PlGF-1 regulates VE-cadherin expression through the
trans-activating Sp1 and Sp3 interaction with the
VE-cadherin promoter
To identify whether VEGF and hPlGF-1 could directly regulate
VE-cadherin gene expression through the trans-activating Sp1 and
Sp3 interaction with the VE-cadherin gene promoter [39] we
analyzed by electrophoretic mobility shift assay (EMSA) the
interaction of a VE-cadherin promoter oligonucleotide probe
(-70/-39), containing the identified GT box (-50/-44) as shown in
Fig. 10a, with the nuclear proteins extracted from endothelial cells.
In unstimulated cells, a single DNA-protein complex was observed
(Fig. 10b). After VEGF, hPlGF-1 or combination treatment, an
additional three DNA-protein binding bands appeared on the gel.
The upper two bands (Sp1 and Sp3, respectively) were much
closer to each other than the remaining slower migrating bands
(Fig. 10b). PlGF induced considerable weak intensities of the
second and third bands compared with the treatments of VEGF
(Fig. 10b,c). In a supershift assay, anti-Sp3 antibody was able to
almost completely shift the second, third and fourth bands,
suggesting that the last two bands also represented Sp3, whereas
anti-Sp1 antibody only partially shifted the first protein-DNA
band (Fig. 10b). Interestingly, in the cells pre-exposed to VEGF,
PlGF reduced significantly the intensity of the second band (Sp3)
without detectable change in the intensities of the first, third and
fourth bands (Fig. 10c).
Discussion
The significance of our observations is that we show hPlGF-1
represents a potent endogenous antagonist of VEGFA-induced
vascular permeability and that this is highly dependent on elevated
VEGF and the timing of the subsequent hPlGF-1 exposure. This
work highlights the potential importance of the precise timing of
the initial administration of anti-VEGF therapies and equal
attention to the time intervals of subsequent dosing. Our results
suggest that repeated treatments with inhibitors of the VEGF
signalling pathway may offer greater success than sustained
inhibition in keeping with nature’s strategy to maintain vascular
health. The mechanisms for blood-retinal barrier breakdown are
complex and the results of the present study provide evidence that
multiple mechanisms are involved. It is noteworthy that the
window of effectiveness for hPlGF-1 is 6 hours after VEGF
treatment, which coincides with the peak of VEGF-induced
vasopermeability [40,41].
The surprising finding that hPlGF-1 can reverse VEGF-induced
pathological vascular permeability, but only during a critical
window of time helps explain some of the controversy surrounding
the reported pro- and anti-angiogenic effects of PlGF [15,30,31].
Here we demonstrate that hPlGF-1 but not hPlGF-2, is a potent
antipermeability factor but only for a few hours after VEGF-A
exposure. Although pre-exposure to hPlGF-1 alone or simulta-
neous hPlGF-1/VEGFA treatment led to increased expression of
VE-cadherin, this was not sufficient to prevent VEGF-induced
permeability. Our data show that the cells need to be primed with
VEGF before they can respond to hPlGF-1 inhibition and utilize
VE-cadherin to stabilize the endothelial junctions. In pathological
neovascularisation, PlGF expression occurs following elevated
VEGF levels [42] leading to the notion that hPlGF-1 stabilizes
Figure 5. PlGF-1 alone stabilizes AJs in microvascular endo-
thelial cells. Representative pictures of confluent cultures of
microvascular endothelial cells treated with hPlGF-1 alone (100 ng/ml)
stained for VE-cadherin (red), claudin-5 (green) and nuclei (DAPI) and
assessed at different times over 24 hours using confocal microscopy.
Scale bar=100 mm.
doi:10.1371/journal.pone.0018076.g005
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in vitro and in vivo studies have relied on knockout or transgenic
mice in which the changes in PlGF expression were sustained
throughout life rather than, as we recreated, pathophysiological
conditions which involve significant oscillations in growth factor
levels.
Figure 6. PlGF-1 stabilizes both AJs and TJs in retinal vessels of mice following VEGF-induced vascular permeability. The upper panel
(a) shows representative confocal images of retinal vessels in flat mount preparations from control (no injection) C57BL/6 mice and animals receive a
1 ml intravitreal injection of: vehicle (PBS); VEGFA; hPlGF-1; simultaneous VEGFA + hPlGF-1; VEGFA followed by hPlGF-1 6 hours later. VEGF was given
at a concentration of 60 ng/ml and hPlGF-1 at 60 ng/ml. 46 hours post the first injection mice received tail vein injections of FITC-labeled albumin.
Two hours later, animals were perfusion fixed with paraformaldehyde. Retinas were prepared as flat mounts and immunostained with VE-cadherin or
claudin-5 (red) and FITC-conjugated agglutinin to visualize retinal vessels. (n=10-20 per group). Scale bar =50 mM. The lower panel (b)shows
representative merged higher power images of retinal vessels stained for VE-cadherin or claudin-5 (red) and FITC-conjugated agglutinin (green). Scale
bar =10 mM.
doi:10.1371/journal.pone.0018076.g006
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PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e18076Figure 7. PlGF-1 reverses VEGF-induced phosphorylation of VE-cadherin followed by claudin-5. Representative immunoblots showing
time-dependent phosphorylation of VE-cadherin (a) and claudin-5 (b) following treatment of endothelial cells with VEGFA alone, hPlGF-1 alone,
simultaneous VEGFA + hPlGF-1 and hPlGF-1 6 hours post VEGF for periods up to 12 hours (n=4 independent experiments). VEGFA and hPlGF-1 were
used at 100 ng/ml. Membrane fractions were immunoprecipitated with PY 20 and Western blot undertaken for VE-cadherin and Claudin-5. Laser
densitometry quantification of immunoblots showing the relative ratio of VE-cadherin (c) and claudin-5 (d) phosphorylation to the heavy chain of
PY20 (n=4 independent experiments). (e) Representative immunoblots and laser densitometry showing the effect of the treatments in (a) on the
phosphorylation status of VE-cadherin Y658 and Y731 (n=4 independent experiments). (1)=VEGFA; (2)=PlGF-1; (3)=PlGF-1 6 hr after VEGFA;
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VEGFR-1. This has significant implications for therapeutic
intervention in vascular diseases. Given that VEGF-E did not
stimulate vascular permeability and neutralization of VEGFR-1
abolished VEGF-A-induced permeability in cultured cells, we
convincingly demonstrated that VEGF-induced permeability is
directed primarily through VEGFR-1 with VEGFR-2 playing a
supportive role. Interestingly, neutralization of either VEGFR-1 and
VEGF-2 in the mouse retina blocked VEGF-induced retinal vessel
leakage further supporting the interdependence of these two
receptors in the regulation of vascular permeability. Given that
VEGFA and hPlGF-1 are clearly both regulating vascular
permeability via VEGFR-1, it would suggest that hPlGF-1 could
inhibit vascular permeability by competing with VEGF-A for
binding to VEGFR-1. However, on endothelial cells the Kdv a l u e s
of VEGF-A to VEGFR-1 and VEGFR-2 range from 9-26 and
Figure 8. PlGF-1 promotes expression of VE-cadherin and reduces cleavage of cell surface VE-cadherin and regulates VE-cadherin
expression. Confluent microvascular endothelial cultures were exposed to VEGFA; hPlGF-1; simultaneous VEGFA + hPlGF-1; VEGFA followed by
hPlGF-1 6 hours later and assessed for total VE-cadherin expression by Western blot. VEGFA and hPlGF-1 were used at 100 ng/ml. (a) Top:
representative immunoblots for VE-cadherin and, upon reblot, a-tubulin. Bottom: laser densitometry analysis demonstrating the relative ratio of VE-
cadherin to the house keeping protein a-tubulin (n=3 independent experiments). (b) The level of cell surface VE-cadherin on microvascular
endothelial cells determined using a cell-based ELISA. Values were calculated as the percent relative to the unstimulated group (n=4 independent
experiments). (c) VE-cadherin mRNA levels quantified using QRT-PCR. Values are displayed as mean transcript copies normalized against GAPDH as
the housekeeping gene (n=3 independent experiments). Data are represented as means 6 s.e.m. *p,0.05, ** by p,0.01 (Mann-Whitney U test).
doi:10.1371/journal.pone.0018076.g008
(4)=simultaneous VEGFA + PlGF-1 and (5)=VEGF A 24 hr after PlGF-1. (f)&( g) The effect of neutralizing antibodies to VEGFR1 or VEGFR2 (2 mg/ml)
on the phosphorylation of VE-cadherin and Claudin-5 treated as described in (a). Data are represented as means 6 s.e.m. *p,0.05, ** by p,0.01
(Mann-Whitney U test).
doi:10.1371/journal.pone.0018076.g007
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PlGFforVEGFR-1 wasshowntobe230 pM[29,46].Analternative
explanation is that although both VEGF and PlGF bind to VEGFR-
1,albeitatdistinctsites,theymayinducedistinctbiological responses
through the phosphorylation of different tyrosine residues within the
intracellular domain of VEGFR-1 [23].
It is unclear why PlGF-1 and PlGF-2 have opposing effects on
VEGF-induced permeability since they both signal through
VEGFR-1 (although PlGF-2 additionally binds to neuropilin-1
and -2) [15,47]. Since most cells in the retina express VEGFR-1
and VEGFR-2 it is possible that PlGF-2 acts indirectly via non-
vascular cells, explaining its lack of effect in vitro on pure
Figure 9. PlGF-1 does not regulate the expression of the TJ proteins claudin-5 or occludin. (a) Confluent microvascular endothelial
cultures were exposed to VEGFA followed by hPlGF-1 6 hours later for varying times and VE-cadherin and claudin-5 mRNA levels quantified using
QRT-PCR. VEGFA and hPlGF-1 were used at 100 ng/ml. Values are displayed as mean transcript copies normalized against GAPDH as the
housekeeping gene (n=3). (b) Using the same experimental conditions, claudin-5 and occludin expression were assessed by Western blot. Left,
representative immunoblots for claudin-5 and occludin and, upon reblot, a-tubulin. Bottom, laser densitometry analysis demonstrating the relative
ratio of claudin-5 and occludin to the house keeping protein a-tubulin (n=3). Data are represented as means 6 s.e.m. *p,0.05, ** by p,0.01 (Mann-
Whitney U test).
doi:10.1371/journal.pone.0018076.g009
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PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e18076Figure 10. PlGF-1 regulates VE-cadherin expression through the trans-activating Sp1 and Sp3 interaction with the VE-cadherin
promoter. (a) Nucleotide sequence of the -169/+20 region of the VE-cadherin gene. All numberings are related to the transcriptional start site (+1).
The sequence belonging to the first exon is boldface. The sequence of oligonucleotide probe is underlined, and putative Sp1 (GT box) is boxed.( b)
Representative EMSA analysis of microvascular endothelial nuclear proteins binding to Sp1 recognition sequences with the promoter of the VE-
cadherin gene in response to vehicle (unstimulated), VEGFA alone, hPlGF-1 alone and hPlGF-1 6 hours following VEGF. VEGFA and hPlGF-1 were used
at 100 ng/ml. VEGFA and PlGF alone or in combination. Supershift complexes were observed with anti-Sp1 and anti-Sp3 antibodies, respectively,
indicating Sp1 and Sp3 binding to the GT box (n=3). From the top to bottom (1) = first band; (2) = second band; (3) = third band and (4) = fourth
band. (c) Quantitative analysis of the trans-activating Sp1 and Sp2 interaction with the VE-cadherin promoter. The fluorescent density of the bands
were normalized to the fluorescent density of VE-cadherin promoter oligonucleotide probe. Data are represented as means 6 s.e.m. *p,0.05, ** by
p,0.01 (Mann-Whitney U test).
doi:10.1371/journal.pone.0018076.g010
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endothelium. Cao and colleagues have proposed that hPlGF-1 acts
by heterodimerization with VEGFA, thus limiting its angiogenic
potential while PlGF-2 acts as a homodimer and proangiogenic
regulator [27,32].
Our data show that hPlGF-1 regulates vascular permeability at
the level of AJs and that changes in TJs are dependent on, and
subsequent to, dephosphorylation of VE-cadherin. The impor-
tance of AJs in maintaining barrier function is derived from data
that shows that genetic deletion of VE-cadherin, or inhibition of
its adhesive function, results in increased permeability and
disruption of endothelium integrity, whereas enhancing VE-
cadherin-dependent adhesion can protect the integrity of
endothelium [7,9,48]. The temporal changes in staining patterns
for junctional proteins together with VE-cadherin phosphoryla-
tion always preceding phosphorylation of claudin 5 endorses the
emerging view that endothelial AJs control TJ integrity [7,36].
The observation that neutralization of VEGFR-2 blocked VEGF-
induced phosphorylation of both VE-cadherin and claudin-5
while neutralization of VEGFR-1 significantly increased phos-
phorylation emphasises the negative regulatory role of VEGFR-1
in vascular permeability and that the ratio of VEGF receptors at
the junctional complexes may determine the integrity of the
junctional complexes.
Our data strongly predicts that targeting AJs rather than TJs
will likely offer an alternative therapeutic option for reducing
vascular permeability. Furthermore, our study demonstrates that
VEGF has the capacity to disassemble endothelial junctions via
reduced availability of VE-cadherin at the cell surface together
with redistribution from cell-cell contacts, rather than by alteration
of VE-cadherin expression. In contrast, hPlGF-1 directly increases
VE-cadherin expression and enhances the density of VE-cadherin
along the interendothelial junctions supporting our conclusion that
hPlGF-1 plays a critical role in the maintenance and stabilization
of vascular barrier function. However, the time-dependent effect
of hPlGF-1 on VEGF-induced permeability is in agreement with
the notion that interendothelial cellular junctions have the
capacity to dissemble and assemble upon various stimulations
and that the restoration of endothelial cell-to-cell contacts requires
the synthesis of VE-cadherin [49]. hPlGF-1 may directly increase
the expression of AJ proteins via the Sp1 family of transcription
factors. The Sp1 family induces conformational change in the
DNA structure to facilitate the recruitment of distal DNA-bound
transcription factors and the assembly of the transcription
initiation complex via protein-protein interaction [50,51]. Recent
studies have revealed that two members of the Sp1 family, Sp1
and Sp3, are known to be co-expressed in several tissue/cell types
including endothelial cells [39,52] and to interact with the
identical consensus such as the GT box[50]. In addition, the
GT box occupies a key position within the VE-cadherin promoter
[51]. hPlGF-1 dramatically reduces the Sp3 binding level from
Sp1/Sp3 complexes. In this sense, the relative levels of Sp1 and
Sp3 in the Sp1/Sp3 complexes may be more crucial than the
absolute amount of Sp1 and Sp3 in term of initiation of VE-cadherin
gene transcription in endothelial cells. Based on the cis-activating
functions of Sp1 and Sp3, we speculate that activation of VEGF
receptors can unconditionally cause Sp1 nuclear translocation and
binding to the VE-cadherin promoter and can induce Sp3 nuclear
translocation which competes or blocks Sp1 binding to the
promoter of VE-cadherin gene.
In conclusion, this work highlights the need for a more complete
understanding of how temporal expression of pro- and anti-
angiogenic agents function in vivo to regulate vascular permeabil-
ity which will be essential in order to maximise the therapeutic
potential of anti-angiogenic therapies and therapies that directly
treat increased vascular permeability.
Materials and Methods
Materials
For in vitro studies, we used recombinant human hPlGF-1(R&D
Systems, Minneapolis, MN, USA) and recombinant human
hPlGF-2 (Cell Sciences, Canton, MA, USA). For in vivo studies,
we used recombinant hPlGF-1 and mouse mPlGF-2 (R&D
Systems, Minneapolis, MN, USA). Recombinant VEGF165 was
purchased from R&D systems (R&D Systems, Minneapolis, MN,
USA) and recombinant Orf Virus-HB-VEGF-E was obtained
from (Cell Sciences, Canton, MA, USA). VEGFA neutralizing
antibody was obtained from (R&D Systems, Minneapolis, MN,
USA) and VEGFR-1 and VEGFR-2 neutralizing antibodies were
obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA).
Microvascular endothelial cell culture
Retinal microvascular endothelial cells were isolated as
previously described [22]. In brief, isolated bovine retinas in ice
cold Eagle’s minimal essential medium (MEM) with HEPES were
homogenized by a Teflon-glass homogeniser and microvessels
trapped on an 83 mm nylon mesh. Vessels were transferred into
26MEM containing 500 mg/ml collagenase, 200 mg/ml pronase
(BDH, UK) and 200 mg/ml DNase at 37uC for 20 min. The
resultant vessel fragments were trapped on 53 mm mesh, washed
with cold MEM and pelleted at 225 g for 10 min. The pellet was
resuspended in microvascular endothelial cell basal medium
(MCDB131) with growth supplement (Invitrogen, CA) at 37uC,
5% CO2 for 3 days. Purity was confirmed by Factor VIII and VE-
cadherin staining. Cells were used between passage 1 and 3.
Growth factor treatment
Confluent endothelial cultures were rendered quiescent for
45 min in serum-free medium. Growth factors, including VEGF-
A, VEGF-E, hPlGF-1 or hPlGF-2 (alone or in combination) were
added at 100 ng/ml, unless stated otherwise, based on our
previous studies [43,53] and in the sequences indicated in the text
for different time periods.
Neutralization of VEGF and VEGFRs in vitro
In some experiments the effect of endogenous VEGF on hPlGF-
1 induced permeability was blocked by co-administration of a
neutralizing antibody against VEGFA (10 mg/ml). To confirm the
relative role of VEGFRs in VEGF and/or hPlGF-1 regulation on
permeability a neutralizing antibody to either VEGFR-1 or
VEGFR-2 (2 mg/ml) was added in combination with the growth
factors as described previously [43].
TER Measurement
Endothelial cells were grown to confluence on porous polyester
membrane inserts (6.5 mm diameter, 0.4 mm pore size; Transwell,
Corning, Cambridge, MA). The upper and lower compartments
contained 100 ml and 0.5 ml of media, respectively. For
experimental treatments, various growth factors were added to
the upper compartment. TER measurements were performed
using an EVOM volt-ohmmeter connected to a 6.5-mm Endohm
unit (World Precision Instruments, Sarasota, FL). At the indicated
time intervals, resistance readings (V) were obtained from each
insert and multiplied by the membrane area (V6cm
2) as values of
TER. The resistance value of an empty culture insert (no cells) was
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treatment in each experiment.
Paracellular permeability assay
Endothelial cells were grown to confluence on porous polyester
membrane inserts (6.5 mm diameter, 0.4 mm pore size; Transwell,
Corning, Cambridge, MA). The growth medium in the upper
chamber was replaced with 100 ml of growth medium containing a
1 mg/ml FITC-dextran 20 or 40 and the cells were equilibrated at
37uC for 15 min. Then different growth factors were added to the
inserts and the insert was moved to a fresh lower well containing
0.5 ml of the growth medium for various periods of times. Samples
from the lower chamber (50 ml) were taken in triplicate and placed
in 96-well cluster plates for measuring fluorescent intensity using a
fluorescent plate reader with excitation at 530 nm and emission at
590 nm.
In vivo retinal permeability measurements
All animal studies were performed under a protocol approved by
the Institutional Animal Care and Use Committee at the University
of Florida, and in accordancewith the ARVO Statement for the Use
of Animals in Ophthalmic and Vision Research. Eight-week-old
C57BL/6 mice were purchased from Jackson Laboratories (Bar
Harbor, ME). Mice received the following intravitreal injections
(1 ml) with a 32-gauge needle into one eye: VEGF; hPlGF-1 or
mPlGF-2; VEGF plus hPlGF-1 or mPlGF-2; 0.9% saline vehicle;
VEGF followed by hPlGF-1 or mPlGF-2 6 or 24 hours later; VEGF
followed by 0.9% saline 6 or 24 hours later. VEGF was given at a
concentration of 60 ng/ml while hPlGF-1 and mPlGF-2 were
injected at 10, 60 or 120 ng/ml. Unstimulated control is the baseline
fluorescence in untreated animals. Forty six hours after the first
injection mice received tail vein injections of FITC-labeled albumin
(0.5 mg in 50 ml vehicle). The mice were returned to their cages and
their cages were placed on heating pads set to low to maintain
normal body temperature. After 2 hours the mice were treated in
two ways: A) For albumin leakage measurements animals were killed
andtheeyethatreceivedtheintravitrealinjectionenucleatedandthe
retinas removed and placed in PBS. The retina were rinsed in buffer
and disrupted mechanically with a polytron homogenizer in 1 ml of
buffer (50 mM ammonium acetate and 150 mM NaCl, pH 7.4),
and cleared by centrifugation at 12,000 g for 15 min at 4uC. The
supernatant fraction was transferred to a new tube, diluted. FITC-
albumin was quantified against a standard curve of FITC-albumin
using a FLUOstar Optima spectrofluorometer (BMG Labtechnol-
ogies) at an excitation wavelength of 485 nm and an emission
wavelength of 520 nm. B) For histology and immunostaining the
mice were perfused by cardiac puncture with 10 ml of 1%
paraformaldehyde in citrate buffer (pH 4.2) which was pre-warmed
to 37uC the eyes that received the intravitreal injection enucleated.
Neutralization of VEGF and VEGFRs in vivo
To confirm the role of VEGFR-1 and VEGFR-2 in VEGF-
induced retinal microvascular permeability microvascular perme-
ability neutralizing antibodies to VEGFR-1 (4 or 12 ng/eye) or
VEGFR-2 (0.5 or 1.0 ng/eye) were given by intravitreal injection
in C57BL/6 mice 6 hours prior to injection of VEGF (60 ng/eye).
46 hours post the first injection mice received tail vein injections of
FITC-labeled albumin and retinas were taken for analysis 2 hours
later (n=6 per group).
Immunocytochemical analysis
Endothelial cells were fixed in 4% paraformaldehyde for 10 min
at room temperature. Subsequently, the cells were washed with
PBS, permeabilized with 0.1% triton X-100 in PBS for 5 min at
room temperature and blocked with 10% normal goat serum in
PBS at room temperature for 30 min. The cells were then
incubated with goat polyclonal anti-VE-cadherin antibody (Santa
Cruz Biotechnology) (1:100), rabbit poly anti-claudin 5 (Cell
Signalling, MA) and rabbit poly anti-ZO-1 (Santa Cruz Biotech-
nology, CA) in PBS containing 1% bovine serum albumin at room
temperature for 1 h, and with the secondary antibody, Alexa Fluor
549-labeled anti-goat IgG (Molecular Probe) (1:1000) for VE-
cadherin and Alexa Fluor 488-labeled donkey anti-rabbit IgG
(Invitrogen, CA) for claudin 5 and ZO-1 in 1% BSA in PBS at
room temperature for 1 hour in dark. Then the cells were
examined and photomicrographs were obtained using a DSU-
Olympus IX81 confocal microscope. Flat mount retinas from the
mouse studies were permeabilized with 0.2% Triton X-100 and
non-specific binding was blocked by 10% normal goat serum in
PBS for overnight at 4uC. The retinas were then transferred to a
solution of primary antibody and incubated for 24 hours at 4uC.
The primary antibodies were rabbit anti-VE-Cadherin (1:100,
Cell Signaling Technology, Inc., Danvers, MA, USA) and rabbit
anti-Claudin-5 (1:3000, Abcam Inc., Cambridge, MA, USA). The
retinas were transferred to the secondary antibody for 24 hours at
4uC after washing in PBS with 0.2% Triton X-100. The secondary
antibody was Cy3 conjugated goat anti-rabbit IgG (1:250). The
retinas were then incubated 30 minutes at room temperature in
1:500 FITC -conjugated agglutinin in 10 mM HEPES, 150 mM
NaCl and 0.1% Tween 20. Retinas were flat mounted onto
microscope slides and covered in aqueous VectaShield mounting
medium (Vector Laboratories, Inc., Burlingame, CA, UAS) for
observation by confocal microscopy. Digital confocal images were
captured with an Olympus DSU-Olympus IX81 confocal micro-
scope with identical photomultiplier tube gain settings. Maximum
projections generated from z-section stacks of confocal images are
processed identically in experimental and control retinas.
Western blotting analysis
VE-cadherin protein expression was assessed in the cell lysates
through standard Western blotting analysis. Equal amounts of
protein from each samplewere resolved by 10% SDS polyacrylamide
gel and transferred onto nitrocellulose membrane. The membranes
were incubated with goat polyclonal anti-VE-cadherin, and rabbit
polyclonal anti-Occludin, anti-claudin 5 and anti-ZO-1 antibodies
(1:250, Santa Cruz Biotechnology, CA, USA; Cell Signalling,
Canton, MA, USA) at room temperature for 2 hr. a-tubulin acted
as the loading control. The membranes were then washed with 5%
milk/TBScontaining0.05% Tween-20followed by HRP-conjugated
secondary antibody (Santa Cruz Biotechnology, CA, USA) (1:4000)
at room temperature for 1 hr. Following washing, the membranes
were incubated with ECL (Santa Cruz Biotechnology, CA, USA) and
exposed to Biomax MR film. Band intensity was determined by laser
densitometry from a minimum of three separate experiments.
RT-PCR analysis of VE-cadherin, claudin 5, Occludin and
ZO-1 expression
Total RNA was isolated from cells treated with growth factors
by using TRIzol Reagent (Invitrogen), and then reversed
transcribed using Reverse-iT
TM (Abgene). Bovine VE-cadherin,
claudin 5, Occludin and ZO-1 transcripts were amplified at
1.5 mM MgCl2 using the primer pairs (VE-cadherin, forward: 59-
CTAACAGCCCTTCCTTGCAG-39, reverse: 59- CTTTGAG-
TTGGACCCGTGAT -39; Claudin 5, forward: 59-TCGTCGC-
GCTGTTC GTGACC -39, reverse: 59-ATGGGCACGGTCG-
GGTCGTA-39; Occludin, forward 59-CCGGAAGATGAAAT-
TCTCCA-39, reverse 59-CAGCTCCCATTAAGGTTCCA-39;
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59- TTTTAGGATCACCCGA CGAG-39). As control for the
amount of mRNA input we amplified bovine glyceraldehyde-
phosphate-dehydrogenase (GAPDH) at 54.93uC annealing tem-
perature, 1.5 mM MgCl2 concentration with forward primer 59-
GGGTCATCATCTCTGCACCT-39 and reverse primer 59-
GGTCATAAGTCCCTCCACGA-39. A total of 10 ml aliquots
of amplified products were separated electrophoretically on a
1.5% agarose gel stained with ethidium bromide and illuminated
with UV light and analyzed using NIH Image software.
Real-time quantitative PCR analysis
The CFX 96 Real Time PCR Detection System (BioRad,
Hercules, CA) was used to quantify the mRNA level of VE-
cadherin (copies/ml from internal control) in endothelial cells with
bovine VE-cadherin primers (forward: 59-CTAACAGCCCTT-
CCTTGCAG-39; reverse: 59- CTTTGAGTTGGACCCGTGAT
-39), the Amplifluor system (Intergen Inc, UK), real time-
quantitive polymerase chain reaction (Q-PCR) master matrix
(Abgene, Surrey, UK) and a universal probe (UniPrimerTM).
Real-time conditions were 95uC for 15 min, followed by 65 cycles
at 95uC for 15 s, 55uC for 60 s and 72uC for 20 s. The results of
the test molecules were normalised against levels of b-actin. The
level of the VEGF transcript from a given sample was
automatically calculated by the software from an internal
standard, a method previously described [54].
VE-cadherin cell surface ELISA
Confluent RMEC monolayers were rinsed with MECBM
containing growth supplement and fixed with 4% paraformalde-
hyde in PBS for 20 min. After two washes with PBS containing
0.1%BSA, the cells were incubated with goat polyclonal anti-VE-
cadherin antibody (Santa Cruz Biotechnology) (1:200) for 2 hr.
The cells then washed for three times with PBS containing 0.1%
BSA and incubated with HRP-conjugated secondary antibody
(1:1000). The monolayer was then rinsed four times with PBS
containing 0.1%BSA, followed by one wash with PBS. For
detection, equal parts of the substrate reagents hydrogen peroxide
and 3,39,5,59-tetramethylment were added to each well. After
colour development, 1 N HCl was added to stop the reaction.
Absorbance was measured at 450 nm using ELISA (QuantikineH,
R & D system) according to the manufacturer’s instruction.
Electrophoretic Mobility Shift Assay (EMSA)
Generation of the nuclear extract from cells was performed
using nuclear extraction kit (ChemiconH International, Inc)
according to the manufactory instruction. The protein concentra-
tion was determined by using the BCA protein assay kit (Perbio
Science UK Ltd). The oligonucleotides (59- CATCTGCCCT-
CATCTGGGAATGGGGTGAGGGG -39 and 59- CCCCTCA-
CCCCATTCCCAGATGAGGGCTGATG -39) were synthesized
(Sigma-Aldrich Company Ltd). Four mg of nuclear extracts were
prepared in a final volume of 20 ml containing 34 mM KCl,
5 mM MgCl2, 0.1 mM dithiothreitol, and 3 mg of poly(dI-dC).
After 10 min on ice, the DNA probe was added, and the
incubation was continued for 20 min at room temperature. The
specific antibodies (1:20) were added to the mixture before the
addition of the DNA probe and incubated 20 min on ice. Finally,
the samples were added with 7 ml of a 20% (w/v) Ficoll solution,
and analyzed on 5% non-denaturing polyacrylamide gels in 0.56
TBE. The gels were stained with fluorescence-based EMSA kit
(Molecular Probes, Inc), which uses fluorescent dye for detection-
SYBRH Green EMSA nucleic acid gel for DNA. Fluorescence
intensity was determined by laser densitometry from a minimum
of three separate experiments.
Statistical analysis
All experiments were repeated at least three times. The TER,
paracellular permeability and VE-cadherin cell surface ELISA
data at different time points were assessed using a Student’s t test
plus ANOVA for multiple comparisons. The Mann-Whitney test
was used to determine statistical significance in the data of VE-
cadherin expression both obtained using Western blotting analysis
and Q-PCR. Results are expressed as mean6standard deviation.
p,0.05 is considered statistically significant.
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